Orexo reports successful completion of OX51 phase II

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Aug 28, 2013 at 4:45 AM

Orexo reports successful completion of OX51 phase II dose-finding study in prevention of procedure-induced pain

Uppsala, Sweden – August 28, 2013 – Orexo today announced the successful completion of a dose finding study for OX51 in patients undergoing prostate biopsy, as the study met its primary end-point of analgesic efficacy. The placebo controlled study, which tested sublingual administration of 3 different doses of OX51 and placebo, demonstrated a statistically significant dose response with respect to maximal pain experience during the biopsy procedure. Treatment with OX51 was safe and well-tolerated in all dose groups and no effects on local tolerability in any dose group were observed. In addition OX51 showed no effect on quantitative scales for assessment of sedation and drowsiness compared to placebo. OX51 is a novel sublingual formulation comprising alfentanil, which has been developed to meet the fast growing demand for efficient pain management during short-term surgical and invasive diagnostic procedures. The quick onset, absence of sedation and drowsiness, short duration, rapid offset and convenient administration of OX51 makes it suitable for prevention of pain for a multitude of surgical and diagnostic procedures. The market for short-term surgical and diagnostic procedures is large and growing with over 130 million procedures performed annually in the US and EU. This growth is driven by both improvement in technology, and a result of an increasing cost control, which propels a shift in such procedures from an in -patient/hospital setting towards an outpatient setting. This shift has created a major need for improving efficient pain management during the short-term surgical and diagnostic procedures without the full access to all resources otherwise found in a hospital. “OX51 is yet another innovation from Orexo meeting a fast growing need from patients and health care providers. We estimate that the commercial potential of OX51 in short-term surgical and diagnostic procedures not requiring full anesthesia is substantial. With these positive results we will now consult the regulatory agencies to decide the best path forward for OX51, while ensuring that the organization remains focused on the launch of Zubsolv for opioid dependence in 2013, ”said Nikolaj Sørensen, President and CEO. For further information, please contact: Nikolaj Sørensen, President and CEO Tel: + 46-703 50 78 88, Email: nikolaj.sorensen@orexo.com About Orexo Orexo AB is an emerging specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology. Orexo’s expertise is within the area of reformulation technologies and especially sublingual formulations. The company has a portfolio of revenue generating US and EU approved products currently marketed under licence and a pipeline of several reformulations of approved compounds for areas of unmet medical need. Orexo also has collaboration projects with several international pharma companies. Orexo, with its headquarters in Sweden, is listed on NASDAQ-OMX. The largest shareholders are Novo A/S and HealthCap. About OX51 OX51 is the first oral tablet formulation comprising alfentanil, which is being developed for the prevention of acute and intense pain episodes in conjunction with care-related diagnostic or therapeutic procedures. OX51 product characteristics are very attractive for pain treatment during shorter procedures according to market research among physicians and payers. The annual peak sales potential is estimated at around MUSD 250. About Prostate Biopsy There are more than two million procedures of prostate biopsies performed annually in Europe and the US. Most of these procedures are performed in an outpatient setting. The diagnostic biopsy procedure is very standardized and normally involves use of local injection analgesia and use of anesthetic cream, but the resulting pain management is often inadequate and the procedure is often painful. About the OX51-002 Dose-Finding Study This is a double-blind, randomized, placebo controlled study in 180 patients in 17 selected sites in 4 different Europe countries undergoing elective prostate biopsy. The primary objective of this study is to evaluate the analgesic efficacy of OX51 in 3 different doses compared to placebo during the procedure in the chosen population. For information about Orexo AB, please visit www.orexo.com. Orexo is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 10:30 am CET on August 28, 2013.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ornellaia's 2026 Harvest: Adapting to Nature's Whims

A Year Marked by Weather's Unpredictable Dance Nobody said making wine was a walk in the park, and the folks at Ornellaia know better than most how to roll with whatever nature throws their way. The 2026 harvest story is as much about unlocking the secrets of the soil as it is about navigating the quirks of the weather. Situated in Bolgheri, Italy, this year's vintage...

OCI N.V. Secures a Win in Court; EGM Proceeds as Planned

OCI Dodges a Bullet in Amsterdam Court Stepping into the courtroom drama, OCI N.V. just took home a win as the Amsterdam Court of Appeal's Enterprise Chamber gave them a clean bill of health, kicking out the inquiry request from VEB and a bunch of other shareholders. The judges weren't convinced there was anything fishy going on, so they tossed the inquiry petition and...

Gong, Agentforce, Avoma Crowned 2026 CI Champions

Diving Deep into Conversation Intelligence There's a lot to unpack when three software titans hog the spotlight, and that's exactly what's happening in the world of conversation intelligence this year. It's like we've hit the jackpot with Gong, Agentforce Sales, and Avoma carving out their turf as the 2026 Champions, according to the venerable Info-Tech Research Group....

U. of Phoenix and LACCD Launch 3+1 Degree Pathway

Opening the Floodgates for Ambitious Community College Students When it comes to climbing the educational ladder, not everyone starts at the same rung. That's a fact we've all come to terms with in one way or another. Enter the University of Phoenix and the Los Angeles Community College District with a solution to expand educational access. The 3+1 Program: A Cost-Saving...

Decoding CarBravo-Certified vs Traditional Used Cars

What’s Behind Door Number One: CarBravo Certification When you walk onto a car lot these days, it's a mixed bag: shiny badges boasting certifications or basic used car signage. For anyone who's spent time around cars, two types stick out—there’s your CarBravo-certified vehicles and your good ol' used cars. Now, Marissa McCoy and Jill Maniaci from Heidebreicht...

HelloNation Brings 'Edvertising' to NC REALTORS® Event

HelloNation's Bold Step into Real Estate Networking October 8th to the 11th is shaping up to be a pivotal few days in Wilmington, North Carolina. Here’s the scoop: HelloNation, known for its innovative 'edvertising' model, is joining the bustling crowd at the 2026 NC REALTORS® Convention. This isn’t just any get-together—it's the grandest annual jamboree for real...

Duke Energy's Cost-Protection Plan Shields Ratepayers

Shielding Customers From Data Center Costs Let's get right into the thick of it: Duke Energy's latest move is a strategic one, shrouded in industry terms but with a real impact on regular folks' wallets. The company's agreement with heavyweights like Amazon, Google, and Meta aims to protect existing customers in North Carolina from getting hit with the costs of powering...

Merit Expands in New York with Bold Acquisition Move

Merit Financial's Growth Trajectory Takes a Leap You watch the movers and shakers in this game long enough, and you start to see patterns. Merit Financial Advisors is one of those juggernauts you'd better keep an eye on. These folks just scooped up Moldenhauer & Associates—a firm that's been a staple in Orchard Park, New York—for a cool $1.1 billion worth of client...

C3EL Expands Federal Footprint with Strategic Contracts

Pushing Boundaries in Federal Contracts What a ride C3EL's had in Government Fiscal Year 2026! Let me tell you, they’ve bagged a bunch of contracts that’d make any company’s mouth water. Kicking things off, they snagged a prime cybersecurity contract from the U.S. Air Force. Considering our current cybersecurity landscape, that's like striking gold. But they...

Wally Disrupts Dental Industry with $25M Funding

A New Breath of Fresh Air for Dental Care Dental visits—a tedious, costly affair we've all dreaded. So, when Wally rolls out an overhaul in this stale landscape, it's worth taking notice. With $25 million in their pockets from Series A funding led by Maveron, Wally's swaggering in with a plan to flip the script on dental care across the nation. Redefining the Dental...